A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2018

At a glance

  • Drugs BNZ 1 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bioniz
  • Most Recent Events

    • 22 May 2018 Status changed from planning to not yet recruiting.
    • 07 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top